1xbet 후기 Pharmaceutical Co., Ltd.

Tokyo, Japan, January 30, 2009 -- 1xbet 후기 Pharmaceutical Co., Ltd. (Head Office: Tokyo, Japan; President and Representative Director: Taro Iwamoto; hereafter, 1xbet 후기 Pharmaceutical) today announced the establishment of 1xbet 후기 Shanghai Research Institute (hereinafter, OSRI) as its basic research institute for new drug discovery in Zhangjiang Hi-Tech Park, Shanghai. The research facility will go into full scale operation in February, 2009.

OSRI is a fully owned subsidiary of 1xbet 후기 (China) Investment Co., Ltd., 1xbet 후기 Pharmaceutical's holding company in China. OSRI aims to discover innovative compounds focusing on infectious diseases and CNS (central nervous system) disorders in collaboration with other 1xbet 후기 group companies and local research institutes in China.

With institutes conducting basic research in Japan (Tokushima, Shiga and Hyogo) and the U.S.A. (Maryland), 1xbet 후기 Pharmaceutical had been committed to discover innovative compounds leveraging its global research network. The establishment of and the start of operation's at OSRI is expected to expand the existing research network to include China in addition to Japan and the U.S.A.

OSRI's premises are located in a building owned by Eiken Shanghai Co., Ltd., a subsidiary of Eiken Chemical Co., Ltd. with whom 1xbet 후기 Pharmaceutical has a strategic alliance in the field of clinical diagnostics.

Based on the corporate philosophy of '1xbet 후기-people creating new products for better health worldwide', 1xbet 후기 Pharmaceutical is dedicated to contributing to the health of people around the world.

1xbet 후기's R&D Network for Pharmaceutical Products Worldwide

About 1xbet 후기 Shanghai Research Institute